Merck KGaA (FRA:MRK) has been assigned a €130.00 ($152.94) price objective by research analysts at JPMorgan Chase & Co. in a research note issued to investors on Tuesday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 4.59% from the company’s previous close.
A number of other equities analysts also recently commented on MRK. Sanford C. Bernstein set a €115.00 ($135.29) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 7th. Morgan Stanley set a €127.00 ($149.41) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday. Deutsche Bank set a €110.00 ($129.41) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Thursday, August 6th. Independent Research set a €124.00 ($145.88) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Nord/LB set a €108.00 ($127.06) target price on Merck KGaA and gave the company a “neutral” rating in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of €113.69 ($133.76).
Merck KGaA stock opened at €124.30 ($146.24) on Tuesday. The stock’s 50-day moving average is €114.37 and its 200-day moving average is €106.30. Merck KGaA has a 12 month low of €76.60 ($90.12) and a 12 month high of €115.00 ($135.29).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: Why are gap-down stocks important?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.